ArticleThe Lancet regional health. Western Pacific2023

Immunogenicity and safety of heterologous immunisation with Ad5-nCOV in healthy adults aged 60 years and older primed with an inactivated SARS-CoV-2 vaccine (CoronaVac): a phase 4, randomised, observer-blind, non-inferiority trial.

Peng-Fei Jin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.